HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Do DPP-4 inhibitors improve endotherial cell function?

Creative Commons License

Files in This Item:
CurrTrendCardiol1_12.pdf229.42 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Do DPP-4 inhibitors improve endotherial cell function?
Authors: Nomoto, Hiroshi Browse this author
Miyoshi, Hideaki Browse this author →KAKEN DB
Nakamura, Akinobu Browse this author →KAKEN DB
Atsumi, Tatsuya Browse this author →KAKEN DB
Manda, Naoki Browse this author
Kurihara, Yoshio Browse this author
Aoki, Shin Browse this author
Keywords: DPP-4 inhibitor
Endothelial cell function
Issue Date: 2017
Publisher: Allied Academies
Journal Title: Current Trends in Cardiology
Volume: 1
Issue: 1
Start Page: 12
End Page: 14
Abstract: DPP-4 inhibitors have been used to treat patients with type 2 diabetes mellitus. These agents not only provide glycemic control, but also have other favorable effects, including the prevention of atherosclerosis. However, it has not been determined whether these agents can improve or maintain endothelial cell function. We previously reported the results of two prospective studies assessing the effects of incretin agents on flow-mediated dilation in patients with type 2 diabetes mellitus without severe atherosclerotic diseases. These studies showed that both the DPP-4 inhibitor sitagliptin and the GLP-1 analogue liraglutide did not improve endothelial cell function. This report discusses the effects of sitagliptin on early-stage atherosclerosis and beta-cell function.
Type: article
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar )


Feedback - Hokkaido University